Agilus Diagnostics Launches Idylla System for Rapid Cancer Mutation Testing in Under 3 Hours
核心洞察
Agilus Diagnostics (搜索) has launched the automated Idylla molecular diagnostics system at its Mumbai laboratory, delivering cancer mutation results in 2.5 to 3 hours instead of several days.
The cartridge-based platform detects key mutations including EGFR (搜索), KRAS (搜索), NRAS (搜索), BRAF (搜索), MSI, and IDH1 (搜索)/IDH2 (搜索), enabling faster biomarker-driven treatment decisions in precision oncology.
The fully integrated system combines sample processing, nucleic acid extraction, amplification, and detection into a single automated workflow, minimizing manual intervention and pre-analytical variability.
Agilus Diagnostics (搜索) has launched the automated Idylla molecular diagnostics system at its Goregaon laboratory in Mumbai, enabling rapid detection of cancer-related genetic mutations within 2.5 to 3 hours. The launch represents a significant advancement in accelerating clinical decision-making and expanding access to precision oncology in India, where conventional molecular testing methods can take several days to return results.
The Idylla system is a fully integrated, cartridge-based molecular testing platform that combines sample processing, nucleic acid extraction, amplification, and detection into a single automated workflow. By minimizing manual intervention and pre-analytical variability, the system delivers highly accurate and reproducible results in a significantly shorter timeframe compared to traditional approaches.
Addressing a Critical Need in Oncology
Timely identification of actionable biomarkers plays a decisive role in guiding targeted therapies. The platform enables rapid detection of clinically relevant mutations, including EGFR (搜索), which is commonly associated with lung cancer (搜索) in Indian and Asian populations; KRAS (搜索) and NRAS (搜索), key markers in colorectal and pancreatic cancers; and BRAF (搜索), present across multiple tumor types including melanoma (搜索) and colorectal cancer (搜索). Additionally, the system supports detection of emerging biomarkers such as Microsatellite Instability (MSI) and IDH1 (搜索)/IDH2 (搜索), which are increasingly important in determining eligibility for advanced targeted and immunotherapies.
"As precision oncology becomes increasingly central to cancer care, rapid and accurate detection of genetic mutations is emerging as a critical factor in guiding treatment decisions," the company stated. Faster turnaround times can help clinicians initiate appropriate therapies sooner, particularly in cases where treatment decisions are time-sensitive.
Leadership Perspectives
Dr. Anand K, MD & CEO, Agilus Diagnostics (搜索), commented on the launch: "The future of oncology lies not just in advanced therapies, but in the ability to deliver fast, accurate diagnoses that can guide treatment decisions in real time. The introduction of the Idylla system at our Goregaon facility significantly enhances our molecular diagnostics capabilities and strengthens our commitment to precision medicine. By enabling rapid access to critical genomic insights, we aim to empower clinicians with timely, actionable information that can improve treatment outcomes and expand access to quality cancer care."
Dr. Kunal Sharma, Vice President and Head – Integrated Onco-Pathology, Agilus Diagnostics (搜索), added: "Delivering actionable molecular insights within hours can significantly impact cancer care. The Idylla platform enables rapid detection of key mutations such as EGFR (搜索), KRAS (搜索), NRAS (搜索) and BRAF (搜索) with minimal manual intervention and high analytical performance. This is especially valuable in scenarios where time is critical and tissue samples are limited. With this launch, we continue to strengthen our commitment to providing cutting-edge, high-quality precision diagnostics."
Implications for Precision Medicine in India
Experts believe that as targeted therapies continue to expand across multiple cancer types, the need for rapid and reliable molecular testing will become increasingly important. Delays in biomarker identification can postpone treatment initiation, while faster access to genomic information can help clinicians match patients with the most appropriate therapies earlier in the treatment journey.
With this addition, Agilus Diagnostics (搜索) further enhances its integrated oncology diagnostics ecosystem, enabling faster, more efficient biomarker-driven treatment pathways and improved access to advanced cancer care. As India continues to expand access to precision medicine, innovations that shorten testing timelines could play a pivotal role in improving outcomes and advancing personalized cancer care.